We take a look at some of the exciting diabetes research developments announced in October 2025, and what the findings could mean for people living with or affected by diabetes.

MODY is a rare form of diabetes which is different from both type 1 and type 2 diabetes, and runs strongly in families. MODY is caused by a mutation (or change) in a single gene. If a parent has this ...

Save for later Page saved! You can go back to this later in your Diabetes and Me Close ...

Scientists in the United States have announced early results from a pioneering trial testing a new stem cell treatment designed to replace insulin-producing beta cells in people with type 1 diabetes.

Causes of type 1 diabetes It’s normal to wonder if something you’ve done could have caused your type 1 diabetes – or a child’s type 1 diabetes. But there’s nothing you could have done to prevent it.

Devastating diabetes complications costs the UK healthcare system £6.2 billion a year, which highlights not just the seriousness of diabetes but also the importance of getting the right care to people ...

The first ever immunotherapy for type 1 diabetes has been licensed for use in the UK. The Medicines and Healthcare products Regulatory Agency (MHRA) has decided teplizumab, also known as Tzield, is ...

Update, 14 August 2025: The Medicines and Healthcare products Regulatory Agency (MHRA) has licensed teplizumab as the first-ever immunotherapy for type 1 diabetes in the UK. Read our news story to ...

Everything you need to know about type 2 diabetes remission. Find out what type 2 diabetes remission is, how it works, and what the benefits are.

We're going to explore whether an intermittent fasting diet can help you put your type 2 diabetes into remission. What are intermitten ...

Our new data shows that an urgent intervention is needed in diabetes care and type 2 diabetes prevention to lower the number of people living with diabetes or prediabetes. Save for later Page saved!

We’ve joined forces with the National Institute for Health Research (NIHR) to fund a new £2.2 million project, called NewDAWN, led by Professors Susan Jebb and Paul Aveyard at the University of Oxford ...